About this collection
My question begins with the grouping: how did such different substances end up under a country name?
Why these entries
I like a collection that gets more varied the longer it is examined. NAD+ brings the chemistry of an ordinary cell. BPC-157 brings a stomach-protein fragment and the unresolved journey from animal repair to human benefit. Semaglutide and tirzepatide bring substantial clinical programmes, with different populations, comparators and cautions.
The phrase Buy Canadian Peptides makes all of that sound like a single category. I wanted room to examine those differences. I object to flattening: a molecule's origin, a measurement and a country's approval decision each deserve their own description.
This website is a collection of articles about published research. Despite the word “Buy” in its name, it has no checkout or shipping operation, issues no prescriptions and offers no appointments. The name belongs on the masthead of the collection; it describes no service available here.
These articles cannot serve as medical advice for an individual. Personal decisions about medicines need a licensed clinician with the relevant health history, and legal questions need someone qualified in the relevant jurisdiction.
Where curiosity leads next
The scarcity of rigorous human trials and confirmation by unrelated laboratories makes BPC-157 the least satisfying entry for me. For NAD+, the next useful step would be convincing evidence that a biochemical change produces a durable health gain in a defined population. Each would make its entry more interesting than another sweeping claim.
Semaglutide and tirzepatide already ask for a different sort of attention: the burdens of treatment, the people enrolled in each trial and the limits of an average result. Respect for a strong result leaves me just as impatient with inflated descriptions of it.
Canada remains a source boundary here. The references used in this collection do not establish every current Canadian regulatory position. The comparison page says what the available records can support; corrections are welcome when a statement outruns its source.